Why the study?
Does mavacamten treatment improve LVOT gradients, NT-proBNP levels, and NYHA functional class in patients with symptomatic obstructive hypertrophic cardiomyopathy?
Does mavacamten treatment improve LVOT gradients, NT-proBNP levels, and NYHA functional class in patients with symptomatic obstructive hypertrophic cardiomyopathy?
Mavacamten provides durable improvements in hemodynamics, biomarkers, and functional class over a median 62-week follow-up in symptomatic obstructive hypertrophic cardiomyopathy.
May support extended use in symptomatic obstructive HCM; leaves open need for randomized confirmation.
Mavacamten treatment showed clinically important and durable improvements in LVOT gradients, NT-proBNP levels, and NYHA functional class, consistent with EXPLORER-HCM. Mavacamten treatment was well tolerated over a median 62-week follow-up.
No takes yet. Share an insight, caveat, or question.
Rader et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: